03933 UNITED LAB
- 10.300
- -0.280-2.65%
UNITED LAB News
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
United Laboratories Proposes Final, Special Dividend for 2023
The United Laboratories International Holdings (HKG:3933) is proposing to pay a final dividend of 0.28 yuan per share for the year ended Dec. 31, 2023, as well as a special dividend of 0.12 yuan per s
UNITED LAB To Go Ex-Dividend On July 2nd, 2024 With 0.30872 HKD Dividend Per Share And 0.13231 HKD Special Dividend Per Share
May 8th - $UNITED LAB(03933.HK)$ is trading ex-dividend on July 2nd, 2024. Shareholders of record on July 3rd, 2024 will receive 0.30872 HKD dividend per share and 0.13231 HKD special dividend per
Federal Pharmaceuticals (03933) plans to pay a final dividend of $0.28 per share
Federal Pharmaceuticals (03933) announced that it intends to pay a final dividend of $0.28 per share.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Changes in Hong Kong stocks | Federal Pharmaceuticals (03933) rose more than 7% at the end of the session, and the price of insulin continued to stabilize, and the company selected Class A from all 6 products
Federal Pharmaceuticals (03933) rose more than 7% at the end of the session. As of press release, it rose 6.67% to HK$10.2, with a turnover of HK$70.37,700.
聯邦制藥：2023年度報告
Changes in Hong Kong stocks | Federal Pharmaceuticals (03933) rose more than 3%, and the winning bidder in Group A across the insulin collection line is optimistic about its accelerated release
Federal Pharmaceuticals (03933) rose more than 3%. As of press release, it rose 3.41% to HK$9.71, with a turnover of HK$22.403,900.
Federal Pharmaceuticals (03933.HK): Amoxicillin Clavulanate Potassium Tablets passed the consistent evaluation of generic drug quality and efficacy
On April 24, Gelonghui Pharmaceuticals (03933.HK) announced that amoxicillin clavulanate potassium tablets (specification: 0.375g) declared by the Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, were approved by the China National Drug Administration and passed the consistent evaluation of the quality and efficacy of generic drugs. Amoxicillin clavulanate potassium tablets are a penicillin-type broad-spectrum antibiotic. Clinically, it is commonly used to treat infections caused by beta-lactamase-producing bacteria, such as respiratory infections, skin and soft tissue infections, and urinary infections. Its curative effect is clear, safe and reliable, and is clinically based
Guojin Securities: Continued increase in domestic insulin share is expected to drive continued growth in performance
Since May 2022, national special insulin collection has been launched in various provinces and cities. While the price of insulin products has declined, the domestic substitution process has greatly accelerated.
CICC: Maintaining Federal Pharmaceuticals (03933.HK)'s “outperforming the industry” rating target price of HK$10.5
CICC released a research report stating that it maintains the “outperforming industry” rating of Federal Pharmaceuticals (03933.HK), the profit forecast remains unchanged, and the target price is HK$10.5. On April 23, the Joint Pharmaceutical Procurement Office of the State Organization issued the “Announcement of the Results of the National Centralized Drug Procurement (Special Insulin Special) Selection Results”, and all 6 products declared by Federal Pharmaceuticals won the bid in Group A.
Federal Pharmaceuticals (03933.HK): Group A won the bid for the entire insulin collection line, hoping for an opportunity to increase share
Company News On April 23, the Joint Pharmaceutical Procurement Office of the State Organization issued the “National Centralized Drug Procurement (Insulin Special Continuation) Proposed Selection Results Announcement”. All 6 products declared by Federal Pharmaceuticals won the bid 1 in Group A. Review insulin sets
Federal Pharmaceuticals (03933.HK): The company's insulin products are to be selected for centralized drug procurement in the country
Gelonghui, April 23 | Federal Pharmaceutical (03933.HK) announced that the company's wholly-owned subsidiaries, Zhuhai Federal Pharmaceutical Co., Ltd. and the Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd. participated in the bidding process for centralized national drug procurement (insulin special continuation) (“insulin special continuation”) organized by the State Organization Drug Joint Procurement Office on April 23, 2024. The company's insulin products are to be selected for this centralized procurement. All of the company's insulin products participated in this insulin collection competition, and all products were selected in Class A. In 2023, the company will sell the total sales of the products to be selected above
Hong Kong Stock Concept Tracking | Insulin Collection Renewal Results Announced, All 13 Companies Won Bids to Benefit Domestic Companies (with Concept Shares)
The agency determined that domestic insulin companies with the advantages of production capacity scale, brand stickiness, and sales coverage are expected to clearly benefit.
Express News | At the insulin collection contract renewal site, the federal pharmaceutical contract offer was leaked
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Changes in Hong Kong stocks | Federal Pharmaceuticals (03933.HK) rose more than 5%, diet pills welcome new catalytic companies, and GLP-1 pipelines are abundant
Federal Pharmaceuticals (03933.HK) rose more than 5%. As of press release, it rose 5.2% to HK$9.92, with a turnover of HK$18.378 million.
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Analysis
Price Target
No Data
